ArticleOncotarget2016
Mutation profiling of 19 candidate genes in acute myeloid leukemia suggests significance of DNMT3A mutations.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- A Direct Comparison, and Prioritisation, of the Immunotherapeutic Targets Expressed by Adult and Paediatric Acute Myeloid Leukaemia Cells: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2023Pooled it
- Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.Clinical and translational science · 2021Trial
- Molecular Profiling of Acute Myeloid Leukemia in Pakistan: Comprehensive Variant Landscape Revealed by Targeted NGS.International journal of molecular sciences · 2026Article
- BRAF Mutations in Myeloid Neoplasms: Prevalence, Co-Mutation Landscape, and Clinical Outcomes-A Comprehensive Review.Biomedicines · 2026Review
- Molecular abnormalities and clinical features in adult patients with acute myeloid leukemia in Thailand.Diagnostic pathology · 2025Article
- VICatMix: variational Bayesian clustering and variable selection for discrete biomedical data.Bioinformatics advances · 2025Article
- The Effects of Resveratrol, Gallic Acid, and Piperine on the Expression of miR-17, miR-92b, miR-181a, miR-222, BAX, BCL-2, MCL-1, WT1, c-Kit, and CEBPA in Human Acute Myeloid Leukemia Cells and Their Roles in Apoptosis.Biochemical genetics · 2024Article
- Article
- The histone demethylase KDM5C functions as a tumor suppressor in AML by repression of bivalently marked immature genes.Leukemia · 2023Article
- Article
- Mutation profile of acute myeloid leukaemia in a Chinese cohort by targeted next-generation sequencing.Cancer reports (Hoboken, N.J.) · 2022Article
- Analysis of RAS gene mutations in cytogenetically normal de novo acute myeloid leukemia patients reveals some novel alterations.Saudi journal of biological sciences · 2021Article
- Article
- Article
- Recurrent SETD2 mutation in NPM1-mutated acute myeloid leukemia.Biomarker research · 2020Article
- Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- Spectrum of gene mutations identified by targeted next-generation sequencing in Chinese leukemia patients.Molecular genetics & genomic medicine · 2020Article
- Article
- Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment.Precision clinical medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We selected 19 significantly-mutated genes in AMLs, including FLT3, DNMT3A, NPM1, TET2, RUNX1, CEBPA, WT1, IDH1, IDH2, NRAS, ASXL1, SETD2, PTPN11, TP53, KIT, JAK2, KRAS, BRAF and CBL, and performed massively parallel sequencing for 114 patients with acute myeloid leukemias, mainly including those with normal karyotypes (CN-AML). More than 80% of patients had at least one mutation in the genes tested. DNMT3A mutation was significantly associated with adverse outcome in addition to conventional risk stratification such as the European LeukemiaNet (ELN) classification. We observed clinical usefulness of mutation testing on multiple target genes and the association with disease subgroups, clinical features and prognosis in AMLs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.